205 related articles for article (PubMed ID: 8021731)
1. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
5. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
6. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
Hall DJ; Martin DA; Kincaid K
Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
10. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; DiƩras V; Beuzeboc P; Dorval T; PalangiƩ T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
13. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx.
Siu LL; Czaykowski PM; Tannock IF
J Clin Oncol; 1998 Jul; 16(7):2514-21. PubMed ID: 9667272
[TBL] [Abstract][Full Text] [Related]
15. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
Smith MR; Peters WA; Drescher CW
Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
[TBL] [Abstract][Full Text] [Related]
17. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
Muggia FM; Blessing JA; Sorosky J; Reid GC
J Clin Oncol; 2002 May; 20(9):2360-4. PubMed ID: 11981008
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
20. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]